TOVX earnings analysis
What we found in TOVX's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Theriva Biologics reported a Q2 2026 EPS loss of $0.07, missing the $0.05 consensus loss estimate, while the filing excerpt does not provide current-quarter revenue, margin, segment, or free-cash-flow figures. Liquidity deteriorated, with cash of approximately $11.3 million and working capital of $1.6 million at June 30, 2026, versus $13.1 million and $7.5 million, respectively, at December 31, 2025. Management expects cash to fund operations only into Q1 2027, is prioritizing VCN-01, and continues to disclose substantial going-concern uncertainty and a need for additional financing.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Disclosure controls remain effective
- Management reported that disclosure controls and procedures were effective as of June 30, 2026, and stated that no changes during the three months ended June 30, 2026 materially affected internal control over financial reporting.
- Cash runway extends into Q1 2027
- The company stated that cash and cash equivalents were approximately $11.3 million at June 30, 2026 and that current cash is expected to fund operations into the first quarter of 2027.
- Capital focused on VCN-01
- Management intends to focus capital on VCN-01 clinical trials while limiting internal funding for SYN-004, and said existing cash should support commencement of a Phase 2a VCN-01 study and regulatory interactions for a proposed retinoblastoma pivotal trial.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Going-concern and liquidity risk
- The company disclosed substantial doubt about its ability to continue as a going concern for the next twelve months, citing recurring operating losses and the need for additional financing. Cash declined from approximately $13.1 million at December 31, 2025 to $11.3 million at June 30, 2026, while working capital fell from $7.5 million to $1.6 million.
- Additional capital is required
- Operating activities used approximately $5.5 million of net cash during the six months ended June 30, 2026. The company said it may need additional equity or debt financing and warned that failure to obtain funding could delay, reduce or eliminate development programs; equity financing may also cause significant dilution.
- Deferred $5.0 million milestone
- An additional $5.0 million VCN-01 milestone payment has been earned but deferred pending discussions with Grifols. The company warned that payment of this amount would significantly deplete cash and could impair its ability to fund operations and clinical research.
- Strategic-alternative execution risk
- The company newly identified strategic alternatives including an acquisition, merger, reverse merger, business combination or asset sale, but warned that no transaction may occur on favorable terms or within an advantageous timeframe. It also stated that failure to complete a strategic alternative could cause a decline in the common-stock price.
- Clinical program constraints
- Management stated that current cash may not be sufficient for additional VCN-01 trials beyond the planned Phase 2a study, additional SYN-004 trials, or completion of the last cohort of the SYN-004 Phase 1a/2a trial. A broad-indication Phase 3 SYN-004 program is not currently feasible without a partner because of capital constraints.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.07
What they said about what is next.
No explicit numeric revenue or EPS guidance was provided. Management stated that current cash is expected to fund operations into the first quarter of 2027; the company expects to focus capital on VCN-01 and does not intend to provide further internal funding for SYN-004 development.
The filing reads worse than the one before it.
What came before.
- 10-Q · May 5, 2026
- Theriva Biologics reported a significant improvement in its financial performance for Q1 2026, with revenue of $300,000 and a narrower net loss of $2.0 million ($0.05 per share), compared to a net loss of $4.3 million…
- 10-K · March 12, 2026
- Theriva Biologics has re‑focused into oncology following its March 2022 acquisition of VCN and centers its strategy on advancing the oncolytic adenovirus VCN‑01 (intravenous and intravitreal delivery) while monetizing…
- 10-Q · August 11, 2025
- Theriva Biologics reported no revenue and a Q2 2025 net loss of $13,058,000 (EPS -$1.93), larger in dollars than prior-year quarter net loss of $8,316,000. Operating costs rose (notably general & administrative) while…
- 10-K · March 6, 2025
- Theriva Biologics has completed a strategic shift to oncology following its March 2022 acquisition of VCN and is developing the oncolytic adenovirus VCN-01 (administered to 142 patients) with a Phase 2b VIRAGE trial…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing TOVX makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever